Public warned of fly-by-night stem cell procedures, products

Human embryonic stem cells can become any cell in the body. AFP FILE PHOTO

MANILA, Philippines Health authorities warned the public anew on Saturday about health facilities and medical practitioners offering unauthorized stem cell therapy and products.

In an advisory, the Food and Drug Administration said that to date, not one stem cell or human cells, tissues, and cellular and tissue-based products (HCT/Ps) that applied for registration has been registered by the FDA for compassionate or clinical trial use, or general use.

The use of HCT/Ps without the authorization or permission by the FDA is considered illegal, it said, reminding hospitals and health facilities of the provisions of the FDA Act of 2009, which prohibits the manufacture, use, advertisement or sponsorship of unregistered health products.

This warning extends to all unlicensed practitioners from other countries and to tourists who visit the Philippines for leisure and medical needs, the advisory added.

According to FDA acting director general Kenneth Hartigan Go, the FDA recognizes only hematopoietic (pertaining to the formation and development of blood cells) stem cell transplantation, corneal resurfacing with limbal stem cells and skin regeneration with epidermal stem cells as generally accepted standards of health care procedures.

If health institutions are doing these three procedures, they can continue doing them because those are allowed. Go said, adding that the efficacy of the use of stem cells for the treatment of other diseases, such as diabetes, cancer and autism, among others, has yet to be proven.

Go noted that while many spa centers and salons are advertising stem cell therapy and products, none of them has the approval of the health agency.

As of now we have not accredited any health facility offering stem cell therapy yet, Go said.

Several facilities had applied for accreditation but Go said many of these were asked to correct their deficiencies.

Read the original post:
Public warned of fly-by-night stem cell procedures, products

FDA: All but 3 stem cells

Human body parts grown in a lab | Scientists are growing noses, ears and blood vessels

Human body parts grown in a lab For more latest tech news and product reviews SUBSCRIBE to In a north London hospital, scientists are growing noses, ears and blood vessels in the laboratory in a bold attempt to make body parts using stem cells. It is among several labs around the world, including in the U.S., that are working on the futuristic idea of growing custom-made organs in the lab. While only a handful of patients have received the British lab-made organs so far including tear ducts, blood vessels and windpipes researchers hope they will soon be able to transplant more types of body parts into patients, including what would be the world's first nose made partly from stem cells. It's like making a cake, said Alexander Seifalian at University College London, the scientist leading the effort. We just use a different kind of oven. TAGS future for mobile phones, future mobile, future mobile applications, future mobile computing, future mobile phone, future mobile phone technology, future mobile phones, future mobile technology, future of mobile, future of mobile applications, future of mobile computing, future of mobile phone, future of mobile phones, future of mobile technology, future of t mobile, future of the mobile phone, future technology mobile phones, latest mobile phone prices in pakistan, latest mobile phone samsung, latest mobile phone sony ericsson, latest mobile phone technology, latest mobile phone with price latest mobile phones, latest mobile phones and prices, latest mobile phones coming soon, latest mobile phones from samsung, latest mobile phones htc, latest mobile phones in india, latest mobile phones in market, latest mobile phones in pakistan, latest mobile phones in samsung, latest mobile phones in sony ericsson, latest mobile phones in the market, latest mobile phones india, latest mobile phones micromax, latest mobile phones models, latest mobile phones of micromax, latest mobile phones of samsung, latest mobile phones of sony ericsson, latest mobile phones on the market, latest mobile phones price, latest mobile phones price in india, latest mobile phones price list, latest mobile phones prices, latest mobile phones prices in india, latest mobile phones samsung, latest mobile phones sony ericsson, latest mobile phones technology, latest mobile phones touch screen, latest mobile phones with price, latest mobile phones with price list latest mobile phones with prices, latest samsung galaxy mobile latest samsung mobile, latest samsung mobile in india, latest samsung mobile india, latest samsung mobile models, latest samsung mobile phone, latest samsung mobile phone in india, latest samsung mobile phones, latest samsung mobile phones in india, latest smart mobile phones, latest technology in mobile, latest technology in mobile phone, latest technology in mobile phones, latest technology mobile, latest technology mobile phone, latest technology mobile phones, latest technology of mobile phones, latest touch mobile phones, latest touch screen mobile phones, latest windows mobile, mobile technology and business, mobile technology applications, mobile technology company, mobile technology development, mobile technology devices, mobile technology education, mobile technology for business, mobile technology future, mobile technology future, mobile technology healthcare, mobile technology in business, mobile technology in education, mobile technology in healthcare, mobile technology in india, mobile technology information, mobile technology news, mobile technology security, mobile technology services, mobile technology software, mobile technology trends, mobile telecommunication technology, new technology for mobile phones new technology in mobile, new technology in mobile phones, new technology mobile, new technology mobile phone, new technology mobile phones, new technology of mobile, new technology of mobile phones, sony ericson latest mobile, sony ericsson latest mobile sony ericsson mobile, sony ericsson new latest mobile, sony latest mobile phones, sony mobile, sony mobile phones, windows mobile phone, windows mobile phones, wireless and mobile technology, wireless mobile technologytyle, sony mobile,

Read more:
FDA: All but 3 stem cells

FDA: No way spas can do stem-cell therapy

Health authorities on Saturday reissued warnings against health facilities and medical practitioners offering stem-cell therapies or related products, which promise to cure a range of diseases, arrest the aging process or even increase libido.

In an advisory, the Food and Drug Administration stressed that to date not one stem cell or human cells, tissues, and cellular and tissue-based products (HCT/Ps) that applied for registration has been registered by the FDA for compassionate or clinical trial use or for general use.

The use of HCT/Ps without the authorization or permission by the FDA is considered illegal, it said. The agency warned hospitals and health facilities of the provisions of the FDA Act of 2009, which prohibits the manufacture, use, advertisement or sponsorship of unregistered health products.

This warning extends to all unlicensed practitioners from other countries and to tourists who visit the Philippines for leisure and medical needs.

According to FDA acting director general Kenneth Hartigan Go, the FDA recognizes only hematopoietic (pertaining to the formation and development of blood cells) stem-cell transplantation, corneal resurfacing with limbal stem cells and skin regeneration with epidermal stem cells as generally accepted standards of healthcare procedures.

If health institutions are doing these three procedures, they can continue because those are allowed, Go said.

But the efficacy of the use of stem cells for the treatment of other diseases, such as diabetes, cancer and autism, among others, have yet to be proven, he said.

Go noted that while many spa centers and salons are advertising stem-cell therapy treatment and products, none of them have secured the FDAs approval. As of now, we have not accredited any health facility offering stem-cell therapy yet.

Applicants with deficiencies

Original post:
FDA: No way spas can do stem-cell therapy

Family boost for infertile men

A British expert said the stem cell research challenged the widely held view that the "door is closed" on men with the problem who want to have children.

Although still at a very early stage, the study raises the future prospect of lab-grown sperm that could allow them to become fathers.

Loading article content

More immediately, it offers researchers a new way to study sperm development and assisted conception treatments.

Lead scientist Dr Reijo Pera, of Stanford University, America, said: "Our results are the first to offer an experimental model to study sperm development. Therefore, there is potential for applications to cell-based therapies in the clinic, for example, for the generation of higher quality and numbers of sperm in a dish.

"It might even be possible to transplant stem-cell-derived germ cells directly into the testes of men with problems producing sperm."

Infertility affects 10% to 15% of couples and in men often has a genetic origin, most commonly the loss of key genes on the male Y chromosome.

All three infertile men taking part in the study had missing regions of Y chromosome DNA associated with the production of few or no sperm.

Fibroblast connective tissue cells from skin samples taken from the men were first genetically engineered to transform them into induced pluripotent stem cells.

These are adult cells whose developmental clock has been turned back so they assume the properties of embryonic stem cells.

Continue reading here:
Family boost for infertile men

Additional Tickets Released for Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New …

New York, NY (PRWEB) May 02, 2014

Stem Cell Institute is releasing additional tickets for its Adult Stem Cell Therapy Clinical Trials seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

After booking its original meeting room beyond capacity, the Stem Cell Institute has reserved a larger room to accommodate additional attendees. The seminar will now take place in the Beekman Room, 2nd Floor, East Corridor of the New York Hilton Midtown.

Those interested in attending are encouraged to register promptly. Only 75 additional seats are available.

Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Special guest speaker:

Here is the original post:
Additional Tickets Released for Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New ...

Stem Cell Therapy Market (Autologous & Allogeneic) Worth $330 Million in 2020 – New Report by MarketsandMarkets

(PRWEB) May 02, 2014

The report Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Asia-Pacific, Europe, and the Rest of the World (RoW).

Browse 57 market data tables 32 figures spread through 196 Slides and in-depth TOC on Stem Cell Therapy Market http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Early buyers will receive 10% customization on report.

This report studies the global stem cell therapy market over the forecast period of 2015 to 2020.The market is poised to grow at a CAGR of 39.5% from 2015 to 2020, to reach $330million by 2020.

Download Free PDF Download @ http://www.marketsandmarkets.com/pdfdownload.asp?id=48

The global stem cell therapy market on the basis of the mode of treatment is segmented into allogeneic and autologous stem cell therapy. In addition, based on the therapeutic applications, the global stem cell therapy market is segmented into eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others.

Inquire Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48

A number of factors such as the increasing funding from various government and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are stimulating the research activities for stem cell therapies. Developing markets, emergence of induced pluripotent stem (iPS) cells as an alternative to embryonic stem cells (ESCs), and evolution of new stem cell therapies represent high growth opportunities for market players.

In 2015, North America will hold the largest share of the global stem cell therapy market. This large share is primarily attributed to the extensive government funding and increasing fast-track approval for stem cell therapeutics by the FDA. Moreover, development of advanced genomic methods for stem cell analysis and high number of ongoing research activities are further fueling the growth of the stem cell therapy market in North America. However, the Asia-Pacific stem cell therapy market is expected to grow at the highest CAGR in the forecast period, owing to factors such as increasing regulatory support through favorable government policies, strong product pipelines, and increasing licensing activities in this region.

More here:
Stem Cell Therapy Market (Autologous & Allogeneic) Worth $330 Million in 2020 - New Report by MarketsandMarkets

Stem cell innovation study converts skin cells to sperm cells in potential infertility treatment

May 2, 2014 7:02 pm by Stephanie Baum | 0 Comments MedCity News

In the latest stem cell innovation, a group of researchers from Stanford University successfully converted skin cells to stem cells to sperm cells, raising new questions about a potential path to treat infertility. The study was published in Cell Report.

The research used skin samples from five men with a genetic mutation calledazoospermia a genetic mutation that prevented them from making mature sperm.

According to a description of the study on NPRs website, researchers took skin cells from infertile men and transformed them into pluripotent stem cells, which can be converted into any cell in the body. The cells were inserted in mice testes and became immature human sperm cells.

The research is certainly at the early stage and experts caution it will take a lot more research to develop healthy sperm but it is already drawing mixed responses from the research world. Although its been called provocative, Dartmouth bioethicist Ronald Green got particularly dark and called attention to the downside. He speculated that it could lead to thefts of tissue samples or hair from the dead to recreate the dearly departed.

Get our daily newsletter or follow us.

Please enter your email below:

More:
Stem cell innovation study converts skin cells to sperm cells in potential infertility treatment

Stem Cells Of Infertile Men Used To Create Preliminary Sperm Cells

April Flowers for redOrbit.com Your Universe Online

A new study, from the Stanford University School of Medicine and Montana State University, demonstrates that, when implanted into the reproductive system of a mouse model, stem cells created from adult, infertile men will yield primordial germ cells. Primordial germ cells normally become sperm cells.

The findings, published in Cell Reports, help to further our understanding of a genetic cause of male infertility and basic sperm biology. The research team says that their approach holds considerable potential for clinical applications.

All of the infertile male participants suffer from a genetic mutation that prevents their bodies from producing mature sperm. The study suggests that the men with this condition called azoospermia might have produced germ cells at some point in their early lives, but these cells were lost as the men matured to adulthood.

Our results are the first to offer an experimental model to study sperm development, said Renee Reijo Pera of the Institute for Stem Cell Biology & Regenerative Medicine and Montana State University. Therefore, there is potential for applications to cell-based therapies in the clinic, for example, for the generation of higher quality and numbers of sperm in a dish.

It might even be possible to transplant stem-cell-derived germ cells directly into the testes of men with problems producing sperm, she added. Considerable study to ensure safety and practicality is needed, however, before reaching that point.

Infertility is a fairly common problem, affecting between 10 and 15 percent of couples in the US. The researchers say that many men are affected by genetic causes of infertility, most commonly due to the spontaneous loss of key genes on the Y sex chromosome. Until now, the causes of infertility at the molecular level have not been clear.

The fact that the research team was able to create primordial germ cells from the infertile men is very promising, but they note that these stem cells created far fewer of these sperm progenitors than the stem cells of men without the genetic mutations. They are sure, however, that this research provides a much needed model to study the earliest steps of human reproduction.

We saw better germ-cell differentiation in this transplantation model than weve ever seen, said Reijo Pera, former director of Stanfords Center for Human Embryonic Stem Cell Research and Education. We were amazed by the efficiency. Our dream is to use this model to make a genetic map of human germ-cell differentiation, including some of the very earliest stages.

Humans share many cellular and physiological processes with common laboratory animals such as mice or fruit flies. In reproduction, however, there are significant variances, making it challenging to recreate the human reproductive processes in a laboratory setting. In addition, many crucial steps, such as the development and migration of primordial germ cells to the gonads,occur in the relatively short first days or weeks after conception.

Read this article:
Stem Cells Of Infertile Men Used To Create Preliminary Sperm Cells

Stem Therapy May Improve Survival of Heart Patients

A new review of previous scientific studies has concluded that stem cell therapy may help reduce the number of deaths in heart patients.

The Cochrane Heart Review Group analyzed data from studies involving just over 1,200 patients in 23 randomized, controlled trials.

The group's report on the potential benefits of stem cell heart repair was published online on April 29 in The Cochrane Library. The Cochrane Reviews are systematic assessments of evidence-based research into human health care and health policy.

There were fewer deaths among heart patients receiving stem cell therapy in addition to standard treatment, compared to patients who were treated with traditional therapies alone or with a placebo. Stem cells are primitive master cells that, under the right conditions, can turn into any cell in the body.

The therapy also reduced the chances that patients, with improved heart function, had to be readmitted to the hospital.

The review noted that stem cell therapy could possibly reduce the number of deaths after one year, but the results of larger clinical trials are needed.

The stem cells are taken from a patients own bone marrow and injected into the hearts of patients with ischemic heart disease and congestive heart failure, repairing damaged cardiac tissue.

Dr. Enca Martin-Rendon, author of the review in Britain, said, This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, Martin-Rendon noted it is difficult to come to any concrete conclusions until larger clinical trials are carried out.

Read more:
Stem Therapy May Improve Survival of Heart Patients

Scientists Produce Personalized Stem Cells For Specific Diseases

By Estel Grace Masangkay

An independent group of scientists led by experts at the New York Stem Cell Foundation Research Institute (NYSCF) reported that they have manufactured the first disease-specific line of embryonic stem cells made with a patients DNA. The achievement is heralded as a major breakthrough in the regenerative medicine field.

This is also the first time cloning technologies have been utilized to generate genetically matched stem cells. The team used somatic cell nuclear transfer to successfully clone a skin cell from a 32 year old female patient with Type 1 diabetes. The cells were transformed into insulin-producing cells similar to lost beta cells in diabetes, which could provide better treatment or even a cure for T1D.

Susan Solomon, CEO and co-founder of NYSCF, says she is excited about the successful production of patient-specific stem cells using somatic cell nuclear transfer (SCNT). CEO Solomon said she became involved with medical research when her son was diagnosed with T1D.

Dr. Egli, scientist from the New York Stem Cell Foundation Research Institute and who led the research, said, From the start, the goal of this work has been to make patient-specific stem cells from an adult human subject with type-1 diabetes that can give rise to the cells lost in the disease. By reprograming cells to a pluripotent state and making beta cells, we are now one step closer to being able to treat diabetic patients with their own insulin-producing cells.

The scientists analyzed factors that affect stem-cell derivation after SCNT. They added histone deacetylase inhibitors and protocol for human oocyte activation, which were crucial in delivering them to the stage at which embryonic stem cells can be properly derived. The beta cells produced from the patients own skin cells are autologous and match the patients DNA. Further research is underway at NYSCF and other institutions for the development of strategies to protect existing and therapeutic beta cells from attacks of the immune system.

The research teams work appeared in the journal Nature.

Follow this link:
Scientists Produce Personalized Stem Cells For Specific Diseases